Skip to Content
Morningstar

Insulet Corp PODD

Morningstar Rating
Unlock
Stock XNAS Rating as of
$165.90 −11.63 (6.55%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Insulet Earnings: New Integrations with G7 and Apple Phones Should Drive Growth and Fend Off Rivals

Debbie Wang

Insulet posted strong first-quarter results that generally met our expectations, and we’re holding steady on our fair value estimate. With this fast start to 2024, management has raised its outlook, and now our projections, which had previously extended beyond guidance, fall near the top end of management’s new range. We remain confident in Insulet’s narrow moat, which is supported by intangible assets. While quality of operations isn’t a generally a factor in how we assess durable moat sources, operations is a major strength of Insulet, in our view.

Read Full Report

Price vs Fair Value

View History
PODD is trading at a 118% premium.
Price
$165.90
Fair Value
$736.00
Uncertainty
High
1-Star Price
$796.32
5-Star Price
$662.00
Economic Moat
Pwctq
Capital Allocation
Pgndsynm

Bulls Say, Bears Say

Bulls

We see global growth for the insulin pump market, as Type 1 diabetics embrace continuous subcutaneous insulin infusion therapy for its lower rate of long-term diabetes-related complications.

Bears

With only one product and low switching costs for customers, Insulet is very vulnerable if larger competitors produce similar or superior tubeless insulin pumps.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PODD is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$177.53
Day Range
$162.72–193.30
52-Week Range
$125.82–331.65
Bid/Ask
$164.10 / $167.00
Market Cap
$11.62 Bil
Volume/Avg
3.2 Mil / 916,839

Key Statistics

Price/Earnings (Normalized)
64.55
Price/Sales
7.62
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Mid Growth
Total Number of Employees
3,000
Website
https://www.insulet.com

Competitors

Valuation

View More
Metric
PODD
MDT
ABT
Price/Earnings (Normalized)
 64.5515.3123.91
Price/Book Value
 16.752.134.70
Price/Sales
 7.623.424.55
Price/Cash Flow
 38.4415.0818.36
Price/Earnings
PODD
MDT
ABT

Financial Strength

Metric
PODD
MDT
ABT
Quick Ratio
 2.361.461.16
Current Ratio
 3.512.301.64
Interest Coverage
 6.148.8610.86
Quick Ratio
PODD
MDT
ABT

Profitability

Metric
PODD
MDT
ABT
Return on Assets (Normalized)
 7.81%7.75%10.63%
Return on Equity (Normalized)
 30.26%13.75%20.87%
Return on Invested Capital (Normalized)
 9.66%9.87%14.81%
Return on Assets
PODD
MDT
ABT
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Medical Devices Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ABT
Abbott LaboratoriesZjxlpzwgHdjtg$182.6 Bil
SYK
Stryker CorpYtflxjjtyvGfvw$125.9 Bil
MDT
Medtronic PLCCdlbcwdmkYqmnc$108.3 Bil
BSX
Boston Scientific CorpZptpdstkbHcdxnl$106.9 Bil
EW
Edwards Lifesciences CorpGnwxkqqxykYsdbg$52.3 Bil
DXCM
DexCom IncDgzrxgylVvyy$50.3 Bil
ZBH
Zimmer Biomet Holdings IncQdgjzsdxkYkjh$25.0 Bil
PHG
Koninklijke Philips NV ADRBhkwtyvrPprwq$24.3 Bil
ALGN
Align Technology IncXxphvvpDtvckh$21.1 Bil

Sponsor Center